Search
forLearn
1 / 1 resultsResearch
5 / 233 resultsresearch Comparison of a New 5% Minoxidil Foam and Rogaine in the Treatment of Androgenetic Alopecia in Chinese Men: A Randomized, Double-Blind, Phase III, Equivalence Trial
The new 5% minoxidil foam is as effective and safe as Rogaine® for treating hair loss in Chinese men.
research Effect of Ultraviolet Light on Topical Minoxidil-Induced Hair Growth in Advanced Male Pattern Baldness
UV light does not significantly affect minoxidil's ability to treat male pattern baldness.
research Efficacy and Safety of a New 5% Minoxidil Formulation in Male Androgenetic Alopecia: A Randomized, Placebo-Controlled, Double-Blind, Noninferiority Study
New 5% minoxidil formula safely and effectively treats male hair loss.
research Long-Term Follow-Up of Men with Male Pattern Baldness Treated with Topical Minoxidil
Minoxidil keeps most hair growth from first year and twice-daily use is better with few side effects.
research Five-Year Follow-Up of Men with Androgenetic Alopecia Treated with Topical Minoxidil
Minoxidil treatment increased hair growth for up to 5 years, requiring twice daily application.
Community Join
5 / 23 resultscommunity pyrilutamide phase 2 results right here, thanks to user Glaringbooch
Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
community Kintor Has Completed Enrollment in Phase II Clinical Trial of KX-826 (Pyrilutamide) for Treatment of Male AGA Patients in the US
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community First patient dosed with Pyrilutamide (Kintor) Phase III
First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.